<DOC>
	<DOCNO>NCT00254267</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy AMG 706 patient gastrointestinal stromal tumor control take imatinib mesylate .</brief_summary>
	<brief_title>Evaluate Efficacy AMG 706 Treat Advanced Gastrointestinal Stromal Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Diagnosis histological confirm GIST Had prior imatinib mesylate therapy Has least 1 measurable leasion modify RECIST Central nervous system tumor involvement require treatment History myocardial infraction Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Gastrointestinal Stromal Tumor , Imatinib Mesylate Resistance , Phase2 study , AMG 706</keyword>
</DOC>